Antibodies as Drugs: Engineering and Computational Tools Enabling Clinical Advances (K1)
February 1-4, 2026
| Fairmont Banff Springs, Banff, AB, Canada
Paul Carter, John R. Desjarlais and E. Sally Ward
Scholarship Deadline: Oct. 2, 2025 | Abstract Deadline: Jan. 9, 2026 | Early Registration Deadline: Dec. 3, 2025
| 4:00–8:00 PM |
Registration |
Riverview Lounge |
| 6:00–8:00 PM |
Welcome Mixer |
Riverview Lounge |
| 7:00–8:00 AM |
Breakfast |
Alberta/New Brunswick |
| 8:00–9:00 AM |
Welcome and Keynote Address |
Cascade Ballroom |
| |
Elaine Hurt, AstraZeneca
Lessons Learned from 30 Years of ADC Development |
|
| 9:00–11:15 AM |
Computational Technologies for Antibody Design and Optimization |
Cascade Ballroom |
| |
Charlotte Deane, University of Oxford
How Far are we from Designing an Antibody Therapeutic on a Computer |
|
| |
Peter S. Kim, Stanford University
Unsupervised Evolution of Protein and Antibody Complexes with a Structure-Informed Language Model |
|
| |
Peyton Greenside, BigHat Biosciences
Combining Active Learning with a Rapid Synthetic Biology Platform to Design Therapeutic Antibodies |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
Riverview Lounge |
| 11:15–1:00 PM |
Poster Setup |
Alberta/New Brunswick |
| 11:15–2:30 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Alberta/New Brunswick |
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
Cascade Ballroom |
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
Riverview Lounge |
| 5:00–7:00 PM |
Antibody Activity on Demand - Engineering Strategies to Emerging Clinical Outcomes |
Cascade Ballroom |
| |
Naoka Hironiwa, Chugai Pharmabody Research
Antibody Activation using Ca2+ or ATP-Switches |
|
| |
Carl U Bialucha, Xilio Therapeutics
Talk Title to be Announced |
|
| |
Dikran Aivazian, Adaxion Therapeutics
Engineering of Hypoimmunogenic Biotherapeutics through a Novel bioconjugate Platform |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
Alberta/New Brunswick |
| 7:30–10:00 PM |
Poster Session 1 |
Alberta/New Brunswick |
Tuesday, February 3, 2026
| 7:00–8:00 AM |
Breakfast |
Alberta/New Brunswick |
| 8:00–11:00 AM |
Emerging Antibody-based Modalities and Engineering Strategies |
Cascade Ballroom |
| |
Jo L. Viney, Seismic Therapeutic
AI/ML for Biologics Drug Discovery for Immunology |
|
| |
James A Wells, University of California, San Francisco
Degraders to Attack the Cancer Surfaceomewell |
|
| |
Paul Carter, Genentech, Inc.
Engineering Antibodies to Improve High Concentration Properties for Subcutaneous Delivery |
|
| |
E. Sally Ward, University of Southampton
Targeting Subcellular Trafficking for the Generation of Therapeutics |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
Riverview Lounge |
| 11:00–1:00 PM |
Poster Setup |
Alberta/New Brunswick |
| 11:00–3:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Alberta/New Brunswick |
| 1:45–2:45 PM |
Career Roundtable (Joint) |
Alhambra Ballroom |
| 4:30–5:00 PM |
Coffee Available |
Riverview Lounge |
| 5:00–5:45 PM |
Keynote Address |
Cascade Ballroom |
| |
David Baker, University of Washington
Remote Presentation: Computational Design of Proteins for Therapeutic Applications |
|
| 5:45–7:00 PM |
Antibody-Drug Conjugates |
Cascade Ballroom |
| |
Greg Thurber, University of Michigan
Optimizing ADC Delivery by Avidity/Affinity Tuning |
|
| |
William M Flanagan, Avidity Biosciences, Inc.
Antibody-Oligonucleotide Conjugates |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
Alberta/New Brunswick |
| 7:30–10:00 PM |
Poster Session 2 |
Alberta/New Brunswick |
Wednesday, February 4, 2026
| 7:00–8:00 AM |
Breakfast |
Alberta/New Brunswick |
| 8:00–11:00 AM |
Harnessing the Immune System with Antibodies |
Cascade Ballroom |
| |
Eric Smith, Regeneron Pharmaceuticals, Inc.
CD28 Bispecifics for Costimulation of T Cells |
|
| |
Pamela M. Holland, InduPro
Proximity Labeling to Identify Target Pairs for ADCs and T Cell Engagers |
|
| |
John R. Desjarlais, Xencor, Inc.
T Cell Engagers |
|
| |
Rony Dahan, Weizmann Institute of Science
Recruitment of Dendritic Cells with Bispecifics / Fc Glycoengineering |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
Riverview Lounge |
| 11:00–2:30 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
Cascade Ballroom |
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
Riverview Lounge |
| 5:00–6:15 PM |
Experience with Antibodies Beyond Oncology |
Cascade Ballroom |
| |
Karen Silence, arGEN-X BVBA
Agonist MuSK Antibodies for the Treatment of Myasthenia Gravis |
|
| |
James E Crowe, Jr., Vanderbilt University Medical Center
Human Monoclonal Antibodies for Emerging Infections |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:15–7:00 PM |
Closing Keynote Address |
Cascade Ballroom |
| |
Erica O Saphire, La Jolla Institute for Immunology
New Antibodies Against an Old Virus |
|
| 7:00–7:15 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
Cascade Ballroom |
| 7:15–8:15 PM |
Social Hour with Dinner |
Alberta/New Brunswick |
| 8:00–11:00 PM |
Entertainment |
|
Thursday, February 5, 2026
